Welcome to our dedicated page for Chemomab Therapeutics news (Ticker: CMMB), a resource for investors and traders seeking the latest updates and insights on Chemomab Therapeutics stock.
Chemomab Therapeutics Ltd. reports developments for its clinical-stage biotechnology program in fibro-inflammatory diseases. Recurring updates center on nebokitug, an antibody targeting CCL24, and its clinical evaluation in primary sclerosing cholangitis through the SPRING trial, related open-label extension data, biomarker findings, macrophage-mediated mechanism research, and peer-reviewed or medical-meeting presentations.
Company news also covers financial results, corporate updates, regulatory interactions with agencies, preparations for later-stage development, strategic partnering discussions, capital-raising activity involving American Depositary Shares, and participation in healthcare and rare-disease investor conferences.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Chemomab Therapeutics Ltd. (Nasdaq: CMMB), a biotechnology firm specializing in innovative therapeutics for fibro-inflammatory diseases, announced its participation in the Aegis 2023 Virtual Investor Conference from May 2 to May 4, 2023. Chemomab's management will present a corporate overview on May 3, 2023, at 9:00 AM EDT. The event will be held virtually, and investors can access the webcast through a provided link.
Additionally, Chemomab's corporate development team will attend the BIO International Convention's One-on-One Partnering™ event in Boston from June 5 to June 8, 2023. They encourage registered attendees to schedule meetings via an online portal.
The company focuses on creating therapies like CM-101, a monoclonal antibody aimed at treating severe fibro-inflammatory diseases, backed by ongoing Phase 2 trials.